Leading the Way in Life Science Technologies

GEN Exclusives

More »

June 15, Vol. 27, No. 12

  • Feature Articles

    • BioMarket Trends: Genomics & Impending Market Re...
    • Jonathan Witonsky
    • Life sciences companies that participate in the US genomics market constantly struggle to exploit opportunities surrounding the impending revolutions of personalized medicine, molecular diagnostics, pharmacogenomics, and the $1,000 genome These companies are under great pressures to execute effective growth strategies ... more »
    • Opening the Gates on Ion Channel Drugs
    • Kathy Liszewski
    • Ion channels continue to generate tremendous excitement as therapeutic targets Blockbusters such as Norvasc (hypertension), Ambien (insomnia), and Xanax (anxiety) exemplify how ion channel therapeutics generate more than $12 billion in revenues annually... more »
    • Reducing Attrition in Late-Stage Development
    • Susan Aldridge, Ph.D.
    • Kurt Stoeckli, PhD, vp, member of the global discovery board, and head of lead identification technologies, Sanofi-Aventis (wwwsanofi-aventiscom) sciences and medical affairs, opened the 10th “MipTec” conference in Basel, Switzerland, last month with a perspective on drug discovery as seen ... more »
    • Multiplexing Methods Head to Clinic
    • Kate Marusina
    • High-throughput discovery technologies deliver an astounding quantity of data but often the greater challenge is to identify real targets from the vast body of potential hits Typically, this task requires multiple variations of experimental conditions in hopes of finding meaningful ... more »
    • Improving Drugs with Protein Engineering
    • Trevor Stokes
    • One challenge for protein engineers is to produce biopharmaceuticals that can withstand the proteolytic conditions of the gastrointestinal tract and serum This was one of many challenges discussed at Cambridge Healthtech’s “PEGS Summit” held last month in Boston To meet ... more »
    • Managing Cell-Line Optimization Process
    • Gail Dutton
    • Most research labs can make cells that produce antibodies The trick is making those antibodies in sufficient quantity and quality to use throughout clinical trials and for manufacturing scale-up Speakers at the recent Informa Life Sciences’ “BioProcessing” conference in Paris ... more »
  • Columns

    • Nereus Prospects Oceans for Cancer Drugs
    • Carol Potera
    • April was a very good month for Nereus Pharmaceuticals (wwwnereuspharmcom) In collaboration with the Multiple Myeloma Research Consortium, the company enrolled the first patient in a multicenter Phase I trial of NPI-0052, its drug candidate for multiple myeloma Also, at ... more »
    • OSI Pharma Needs to Expand Pipeline
    • Querida Anderson
    • Tarceva, OSI Pharmaceutical’s (wwwosipcom) oncology drug, certainly has been the prize stallion leading the company’s success Some, however, like Zacks senior drug industry analyst Jason Napodano, are wondering whether the company is simply a one-trick pony... more »